Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(6):501; doi:10.1093/jnci/91.6.501
© 1999 by Oxford University Press
This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 6, 501, March 17, 1999
© 1999 Oxford University Press

NEWS

Five Cervical Studies Show Cisplatin-Based Chemoradiation Reduces Deaths

{bullet} Gynecologic Oncology Group (GOG) 85: The 3-year survival rate is 67% for women receiving radiation with cisplatin and 5-fluorouracil compared to 57% for those receiving radiation therapy and hydroxyurea. (Whitney, C.W., et al., Journal of Clinical Oncology, in press)

{bullet} Radiation Therapy Oncology Group (RTOG) 9001: The 3-year survival rate for women receiving radiation with cisplatin and 5-FU is 75% compared to 63% for women receiving radiation alone. (Morris, M., et al., New England Journal of Medicine, in press; available on the journal's Web site: www.nejm.org.)

{bullet} Gynecologic Oncology Group (GOG) 120: In two groups receiving radiation and chemotherapy including cisplatin, the 3-year survival rate is 65% compared to 47% for women receiving radiation and hydroxyurea. (Rose, P.G., et al., New England Journal of Medicine, in press; available on the journal's Web site: www.nejm.org.)

{bullet} Southwest Oncology Group (SWOG) 8797: The 3-year survival rate for women receiving radiation and cisplatin and 5-FU is 87% compared to 77% for women receiving radiation alone. (Peters, W., et al., to be presented at the annual meeting of the Society of Gynecologic Oncology, March 22, 1999; available on the SGO Web site: www.sgo.org.)

{bullet} Gynecologic Oncology Group (GOG) 123: With half of the patients followed for 35.7 months or more, 83% of those who received concurrent cisplatin and radiation therapy are alive, compared to 74% of those treated with radiation therapy alone. (Keys, H.M., et al., New England Journal of Medicine, in press; available on the journal's Web site: www.nejm.org.)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?